Cellectis (CLLS) Shares Outstanding (2014 - 2026)
Cellectis (CLLS) posted quarterly Shares Outstanding (Entity) of $13.9 million for Q1 2026, little changed year-over-year from $13.8 million in Q1 2025, and little changed quarter-over-quarter from $13.9 million in Q4 2025.
Cellectis (CLLS) Shares Outstanding (2014 - 2026) Analysis & Trends
Cellectis' Shares Outstanding (Entity) history runs 9 years deep, the most recent figure standing at $13.9 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) changed 0.37% year-over-year to $13.9 million; the TTM figure through Mar 2026 stood at $13.9 million (changed 0.37% YoY), while the FY2025 annual figure was $13.9 million, up 10.72% from the prior year.
- Shares Outstanding (Entity) for Q1 2026 stood at $13.9 million, roughly flat from $13.9 million in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $55.6 million in Q2 2023, with the low at $7.9 million in Q4 2023.
- The 5-year median for Shares Outstanding (Entity) is $13.9 million (2025), against an average of $27.4 million.
- The sharpest annual moves came in 2023 and 2024: Shares Outstanding (Entity) sank 82.7% in 2023, then soared 58.85% in 2024.
- Cellectis' Shares Outstanding (Entity) stood at $45.5 million in 2022, then tumbled by 82.7% to $7.9 million in 2023, then jumped by 58.85% to $12.5 million in 2024, then advanced by 10.72% to $13.9 million in 2025, then gained by 0.25% to $13.9 million in 2026.
- Business Quant data shows CLLS's Shares Outstanding (Entity) at $13.9 million in Q1 2026, $13.9 million in Q4 2025, and $13.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Cellectis | 306.61 Mn | 120.95 Mn | - | 100.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 100.53 Mn |
| Dec 31, 2025 | 100.28 Mn |
| Sep 30, 2025 | 100.33 Mn |
| Jun 30, 2025 | 100.23 Mn |
| Mar 31, 2025 | 100.16 Mn |
| Dec 31, 2024 | 90.57 Mn |
| Sep 30, 2024 | 87.36 Mn |
| Jun 30, 2024 | 89.85 Mn |
| Mar 31, 2024 | 71.81 Mn |
| Dec 31, 2023 | 57.01 Mn |
| Sep 30, 2023 | 55.58 Mn |
| Jun 30, 2023 | 55.58 Mn |
| Mar 31, 2023 | 51.45 Mn |
| Dec 31, 2022 | 45.55 Mn |
| Sep 30, 2022 | 45.54 Mn |
| Jun 30, 2022 | 45.51 Mn |
| Mar 31, 2022 | 42.02 Mn |
| Dec 31, 2021 | 44.82 Mn |
| Sep 30, 2021 | 45.47 Mn |
| Jun 30, 2021 | 45.46 Mn |